insights_auto
Why is LCTX up 2.89%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
$0.93
arrow_upward
+2.89%(+0.026) 1D
$0.93
arrow_upward
+0.45% (+0.0042)todayPre-market
Closed: Oct 2, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
$0.92
High
$0.96
Low
$0.89
Mkt. cap
236.38M
Avg. vol.
1.33M
Volume
375.00
52-wk high
$2.09
52-wk low
$0.88
EPS
-$0.14
Beta
1.60
Shares outstanding
252.91M
No. of employees
75
Open
$0.92
High
$0.96
Low
$0.89
Mkt. cap
236.38M
Avg. vol.
1.33M
Volume
375.00
52-wk high
$2.09
52-wk low
$0.88
EPS
-$0.14
Beta
1.60
Shares outstanding
252.91M
No. of employees
75
News stories
From web sources and news partners
BigGo Finance
·
31 minutes ago
Warren Buffett's Singular Investment Advice: Own the S&P 500, but Patience Is the Price
Barron's
·
1 hour ago
What to Watch This Week
VT Markets
·
3 hours ago
Week Ahead: Weak US Jobs Shift Fed Outlook as Gold, USD and S&P 500 React
Simply Wall Street
·
1 hour ago
US Stock Market Today: S&P 500 Futures Climb As Cooler Wages Temper Inflation Concerns
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc